Introduction {#s1}
============

Rationale
---------

Lung and gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are a heterogeneous group of malignancies derived from neuroendocrine cell compartments in various organs ([@B1]). A significant increase in the incidence of NETs over time has been reported ranging from 2.5 to 5 cases per 100,000 in Caucasian population ([@B2]--[@B5]). In unresectable or metastatic NETs, systemic treatment options are limited but in recent years there has been a renewed interest in expanding the therapeutic armamentarium ([@B6]). In particular, whilst in GEP-NETs the activity and safety of several compounds has been explored, in lung NETs only few drugs have been tested and the choice of treatment is often based on GEP-NET studies ([@B7], [@B8]).

NETs have been identified as hypervascular tumours. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are usually overexpressed and are associated with poor prognosis ([@B9]). However, a modest clinical activity with bevacizumab, a monoclonal antibody targeting VEGF, has been observed in advanced neuroendocrine tumours in phase II studies ([@B10], [@B11]). In a phase III trial, sunitinib showed a superior efficacy to placebo in terms of progression-free survival (PFS) (11.4 vs. 5.5 months) leading to FDA and EMA approval for use in patients with advanced pancreatic NETs (pNETs) ([@B12]).

Pazopanib is an oral multitargeted tyrosine kinase inhibitor acting through VEGFR types 1--3, fibroblast-derived growth factor receptors (FGFR 1, 3, and 4), platelet-derived growth factor receptors α and β, and stem-cell factor receptor (c-Kit) ([@B13], [@B14]). Studies *in vitro* have shown that pazopanib inhibits ligand-induced autophosphorylation of VEGFR-2 PDGF-induced phosphorylation of c-Kit and PDGFRβ and VEGF-induced proliferation ([@B13]). *In vivo* pazopanib is known to inhibit FGF- and VEGF-induced angiogenesis in mouse models and has shown antitumour activity in different human models of solid tumours ([@B15]).

In one phase I trial, a patient with unknown primary neuroendocrine tumour obtained a partial response (PR) from treatment with pazopanib ([@B16]). Nevertheless, there are limited and non-conclusive data on the efficacy of tyrosine kinase inhibitors (TKIs) in both pNETs and non-pNETs, especially in those originating from the colorectum and small intestine where the incidence of the disease is high ([@B6], [@B17]).

Objectives
----------

The aim of this systematic review was to evaluate the published studies assessing the activity and safety of pazopanib in patients with metastatic NEN (mNEN).

Research Questions
------------------

1.  \- Activity of pazopanib in patients with mNEN

2.  \- Safety of pazopanib in patients with mNEN

3.  \- Role of pazopanib in the therapeutic scenario of mNEN.

Methods {#s2}
=======

Study Design
------------

We report the results of a phase II systematic review and meta-analysis on the activity and safety of pazopanib in patients with mNEN. This study was performed according to PRISMA guidelines ([@B18], [@B19])(see [Supplementary Materials](#SM1){ref-type="supplementary-material"}). The quality of included studies was assessed using the Downs and Black checklist (D&B checklist), which is appropriate for both randomised and non-randomised clinical trials. This checklist consists of 27 items distributed between five subscales. The total maximum score is 32. A study scoring 16 or more is ranked as a high quality study ([@B20]).

Participants, Interventions, Comparator
---------------------------------------

We included all articles with prospective data on mNEN in adult patients treated with pazopanib. All of the studies included were in the English language.

Systematic Review Protocol
--------------------------

We developed a protocol that had pre-specified objectives, eligibility criteria, data of interest, search strategy, and analysis plan. The present systematic review was registered in the PROSPERO database.

Data Source Study Section and Data Extraction
---------------------------------------------

A search of the major databases Medline/PubMed, Cochrane and Embase was performed to identify publications on pazopanib for the treatment of neuroendocrine neoplasia ([@B21]). Search terms used included "pazopanib" and/or "neuroendocrine." A supplementary search of congress abstracts published between 2014 and 2019 was also carried out for the annual meetings of the American Society of Clinical Oncology (ASCO), ASCO Gastrointestinal Symposium (ASCO-GI), and European Society for Medical Oncology (ESMO). A manual search of the references of retrieved articles for additional relevant publications was also performed. References from systematic reviews and meta-analyses were screened to ensure search sensitivity ([Figure 1](#F1){ref-type="fig"}).
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Two authors independently conducted a preliminary screening of reports by reading titles and abstracts. Duplicate publications were removed. All identified citations were reviewed and those considered unrelated were excluded. The full texts of potentially relevant articles were then downloaded for the second round of screening. When disagreement existed, two authors discussed with a third reviewer to reach a final decision. Data from included studies describing the population treated as well as treatment efficacy and toxicity parameters were extracted and pooled.

For each study, the following data were collected and tabularised for the analysis: year of publication, name of the first author, area of study; study design; baseline characteristics of patients included; intervention including regimens, dosages and cycles; outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS); toxicities including those of a haematological and non-haematological nature.

Statistical Analysis
--------------------

For survival primary endpoints, meta-analyses usually deal with hazard ratios which can only be obtained when the experimental treatment is compared to a control treatment. However, single-arm exploratory phase II studies aimed at estimating the survival curve are far from rare, especially in the area of rare tumours. In this scenario, the PFS and OS curves are usually summarised by medians and accompanied by their 95% confidence interval (95% CI), as is the case of the present review. Following the method used by McGrath et al., pooled estimates were obtained as the median of the study-specific PFS and OS medians ([@B22]), whereas the corresponding 95%CIs were obtained as the $1/2 \pm \min\left\{ {1/2,\ z_{0.975}/{({2\sqrt{K}})}} \right\}$ quantiles of the *k* observed study medians, with *z*~α~ the α quantile of the standard normal distribution.

Heterogeneity between the median PFS and OS of studies was evaluated using the *I*^2^ index that quantifies values higher than 50%, indicating sizable heterogeneity. Furthermore, the Cochran *Q*-test was used to infer the null hypothesis between study homogeneity at a significance level α = 0.10.

All of the statistical analyses were performed with the statistical language R version 3.6.1. The metamedian package was used to compute the pooled estimates and their 95% CIs, while the *ad hoc* code was used to compute the *I*^2^ index and infer homogeneity via the Cochran *Q*-test.

Results {#s3}
=======

Study Selection and Characteristics
-----------------------------------

The systematic search of the literature identified four studies meeting selection criteria ([Figure 1](#F1){ref-type="fig"}): three peer-reviewed journal publications \[([@B23]--[@B25]) and one conference abstract/poster ([@B24])\]. Briefly, one randomised and three non-randomised prospective phase II studies included a total of 304 patients of whom 74 were treated with placebo. Three studies were multicentric and only one was monocentric ([@B23]). Two studies had an independent review ([@B23], [@B26]). All the studies were of high quality according to the D&B checklist. Patient number, tumour histology (grade and primitive site), Eastern Cooperative Oncology Group Performance Status (ECOG PS) and other characteristics of each study are shown in [Table 1](#T1){ref-type="table"}.

###### 

Principal characteristics of the Phase II studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**              **Country**   **Phase**   **Type of publication**   **Randomised vs. placebo**   **No. of patients**   **Grade**   **Primitive site**   **ECOG PS**   **Biomarker evaluation**   **Setting**
  --------------------------- ------------- ----------- ------------------------- ---------------------------- --------------------- ----------- -------------------- ------------- -------------------------- -----------------------------
  Ahn et al. ([@B23])         Asia          II          Full Text                 No                           37                    G1\         Pancreas GI\         0--1          No                         Metastatic only
                                                                                                                                     G2\         Lung\                                                         
                                                                                                                                     G3          Unknown Other                                                 

  Phan et al. ([@B24])        US            II          Full Text                 No                           52                    G1\         GI\                  0--1          No                         Metastatic/locally advanced
                                                                                                                                     G2          Pancreas                                                      

  Grande et al. ([@B25])      Europe        II          Full Text                 No                           44                    G1\         Pancreas GI\         0--1          Yes                        Metastatic/locally advanced
                                                                                                                                     G2          Lung\                                                         
                                                                                                                                                 Unknown Other                                                 

  Bergsland et al. ([@B26])   US            II          Abstract                  Yes                          171                   G1\         Pancreas GI\         0--1          Yes                        Metastatic/locally advanced
                                                                                                                                     G2\         Lung Other                                                    
                                                                                                                                     UK                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ECOG PS, Eastern Cooperative Oncology Group Performance Status; GI, gastrointestinal*.

Summary of Findings
-------------------

### Population Characteristics

A total of 304 patients were included in the selected trials. Progressive disease during other previous treatment was found at the time of enrolment in 283 (93.1%) patients. Previous therapies included somatostatin analogues (SSA) in 177 (58.2%) patients, other TKIs in 16 (5.2%), everolimus in 25 (8.2%), both TKI and everolimus in 8 (2.6%), chemotherapy in 56 (18.4%), hepatic locoregional treatment in 38 (12.5%) and other non-specified treatments in 19 (6.2%). One hundred fourteen (37.5%) patients had tumours of gastrointestinal (GI) origin, while the remaining (190, 62.5%) had NEN of lung, pancreatic and unknown origin. The majority of patients (76.3%) had grade 1 or 2 NEN and 15 (5%) had grade 3 NEN. Tumour grade was unknown in 58 (18.7%) patients. Seventy patients had a functioning tumour (23%). SSAs were administered together with pazopanib in 230 (75.6%) patients.

Clinical Outcomes
-----------------

The intention-to-treat population treated with pazopanib comprised 230 patients, excluding 74 patients in the Bergsland study who were treated with placebo. [Table 2](#T2){ref-type="table"} shows the study sample sizes or those of the various study arms when reported in the protocol. Median PFS and OS, reported in months, are also included along with their 95%CIs, whenever available. The data derive from single-arm phase II studies, with the exception of Bergsland et al.\'s study ([@B26]) which was a phase II randomised controlled trial (for the purposes of this review we only considered the experimental pazopanib arm). Phan et al. ([@B24]) reported distinct median PFS and OS for patients with pNETs and carcinoid tumours, respectively. Ahn et al. ([@B23]) did not evaluate OS and therefore the pooled median was based on the remaining values. Bergsland et al. ([@B26]) did not report 95%CIs for PFS or OS. A response to pazopanib was reported in 186 patients. The studies registered stable disease (SD) in 148 (79.5%; range: 95% CI 61.7--92.1%) patients, partial response (PR) in 20 (10.7%; 95% CI, range 2.6--20.5%) and progressive disease (PD) in 18 (9.7%; 95% CI range: 5.8%−17.6%). No complete responses were observed. The DCR was 90.3%. Median PFS and OS from all trials was 11.6 (95% CI: 9.2, 13.9) and 24.6 (95% CI: 18.7, 40.8) months, respectively ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).
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###### 

Sample sizes and median PFS and OS in months along with their 95% confidence intervals (CIs).

  **Study**                   **Stratification**   **Sample size**   **Median PFS (95% CI)**   **Median OS (95% CI)**
  --------------------------- -------------------- ----------------- ------------------------- ------------------------
  Ahn et al. ([@B23])         --                   37                9.1 (4.9, 13.3)           --
  Phan et al. ([@B24])        Pancreatic NETs      32                14.4 (5.9, 22.9)          25.0 (15.5, 34.4)
                              Carcinoid tumours    20                12.2 (5.3, 19.0)          18.5 (15.0, 22.0)
  Grande et al. ([@B25])      --                   44                9.5 (4.8, 17.1)           24.1 (20.0, 28.3)
  Bergsland et al. ([@B26])   --                   97                11.6 (NA, NA)             41.3 (NA, NA)

*PFS, progression-free serviva; OS, overall survival; NA, not applicable*.

Side-Effects
------------

Safety outcomes are presented in [Table 3](#T3){ref-type="table"}. The rate of G1-G4 toxicities experienced was 70%. The most frequent adverse events were fatigue (65%), hypertension (50%), neutropoenia (26.5%), mucositis (16%), H&F syndrome (15.6%), thrombocytopoenia (15.2%), anaemia (9.1%) and proteinuria (4.7%). The rate of grade (G)3-4 toxicity was 45.2%. The most frequent G3-G4 adverse event was hypertension (15.6%).

###### 

List of side-effects grouped by grade.

                                           **Grade 1-2**   **Grade 3-4**   **All grade**
  ---------------------------------------- --------------- --------------- ---------------
  **Haematological side-effects**                                          
  Anaemia                                  16 (80.0)       4 (20.0)        20 (100)
  Neutropoenia                             40 (87.0)       6 (13.0)        46 (100)
  Thrombocytopoenia                        34 (97.1)       1 (2.9)         35 (100)
  **Non-haematological side-effects**                                      
  Abdominal pain                           45 (91.8)       4 (8.2)         49 (100)
  Alkaline phosphatase                     9 (90.0)        1 (10.0)        10 (100)
  Alopoecia                                7 (100)         0               7 (100)
  Anorexia                                 34 (94.4)       2 (5.6)         36 (100)
  AST/ALT increase                         124 (83.8)      24 (16.2)       148 (100)
  Asthenia                                 30 (81.1)       7 (18.9)        37 (100)
  Blood bilirubin increase                 29 (93.5)       2 (6.5)         31 (100)
  Confusion                                0               1 (100)         1 (100)
  Constipation                             8 (100)         0               8 (100)
  Dehydration                              0               1 (100)         1 (100)
  Diarrhoea                                114 (89.8)      13 (10.2)       127 (100)
  Dizziness                                7 (100)         0               7 (100)
  Oedema                                   9 (100)         0               9 (100)
  Erythema                                 5 (100)         0               5 (100)
  Fatigue                                  103 (89.6)      12 (10.4)       115 (100)
  Fever                                    7 (100)         0               7 (100)
  H&F syndrome                             34 (94.4)       2 (5.6)         36 (100)
  Hair depigmentation                      11 (100)        0               11 (100)
  Headache                                 17 (100)        0               17 (100)
  Hepatotoxicity                           8 (53.3)        7 (46.7)        15 (100)
  High GGT                                 5 (100)         0               5 (100)
  High LDH                                 7 (100)         0               7 (100)
  Hyperglycaemia                           15 (83.3)       3 (16.7)        18 (100)
  Hypertension                             79 (68.7)       36 (31.3)       115 (100)
  Hypertriglyceridaemia                    0               1 (100)         1 (100)
  Hypocalcaemia                            7 (100)         0               7 (100)
  Hypokalaemia                             1 (50)          1 (50)          2 (100)
  Hypomagnesaemia                          9 (100)         0               9 (100)
  Hypophosphataemia                        5 (100)         0               5 (100)
  Hyporexia                                7 (87.5)        1 (12.5)        8 (100)
  INR increase                             7 (100)         0               7 (100)
  Insomnia                                 5 (100)         0               5 (100)
  Mucositis                                37 (100)        0               37 (100)
  Nausea                                   123 (96.1)      5 (3.9)         128 (100)
  Pain                                     19 (90.5)       2 (9.5)         21 (100)
  Pancreatitis                             0               1               1 (100)
  Proteinuria                              7 (63.6)        4 (36.4)        11 (100)
  Pruritus                                 4 (100)         0               0 (100)
  Rash                                     18 (94.7)       1 (5.3)         19 (100)
  Skin and subcutaneous tissue disorders   6 (100)         0               6 (100)
  Skin hypopigmentation                    7 (100)         0               7 (100)
  Drowsiness                               6 (100)         0               6 (100)
  Thromboembolic events                    0               1 (100)         1 (100)
  Urinary tract infection                  0               1 (100)         1 (100)
  Vomiting                                 41 (9.1)        4 (8.9)         45 (100)

Risk of Bias
------------

The studies included in this systematic review were phase II studies. The fact that we included the survival estimates of the pazopanib arm in Bergsland et al.\'s study ([@B26]) eliminates the potential drawbacks of considering trials with different designs. Similarly, the study by Phan et al. ([@B24]) reported distinct median PFS and OS for both pNET and carcinoid tumour arms. We considered these values in the meta-analysis because they came from different studies. The relative similarity between median survival estimates, especially for PFS, partially safeguarded against extreme results.

Discussion {#s4}
==========

Summary of Main Findings
------------------------

Phase II trials provide a valuable insight into diseases, treatment efficacy and safety, especially in settings where is it difficult to carry out large randomised phase III clinical studies i.e., in the area of rare tumours. In a phase II setting, surrogate endpoints are usually taken into consideration as an early sign of drug activity and can facilitate the decision-making about whether to proceed with phase III testing. Sunitinib is still the only approved TKI for the treatment of advanced pNETs, showing a clear impact in terms of PFS and ORR. However, despite an initial benefit, sunitinib inevitably loses its effectiveness because of the activation of downstream pathways that induce resistance, leading to increased invasiveness and metastasis ([@B27], [@B28]). Peptide radionuclide receptor therapy (PRRT), chemotherapy and everolimus are other therapeutic options, but patients progressing on these treatments are left with few, if any, alternatives ([@B29]).

To the best of our knowledge, the present systematic review is the first to assess phase II literature on the effectiveness of pazopanib in NEN. Pazopanib achieved a DCR of 91.3% and a median PFS and OS of 11.6 and 24.6 months, respectively, superior to results of other targeted therapies in the same setting (DCR ranging from 72 to 84% and median PFS of 11--12.6 months) ([@B12], [@B30]--[@B32]). Of note, although half of the patients were pretreated, the pazopanib activity was maintained. Furthermore, the addition of SSAs would appear to promote a synergistic effect, increasing the DCR in this patient subgroup. A recently published network meta-analysis supports this hypothesis of the additional effect of the SSA combination with other therapies ([@B33]).

Recently, some phase II trials have been carried out to obtain a breakthrough therapy designation from the regulatory authorities for tumours whose therapeutic armamentarium is limited ([@B34], [@B35]). However, the interpretation of data from phase II trials has faced difficulties because of the lack of a control group, hampering direct and scientifically robust comparisons, and small patient samples. The added value of a phase II systematic review and meta-analysis could help to overcome the problem of sample size for patients treated in single trials and amplify the efficacy data of a drug evaluated prospectively in small studies.

Safety profile is also crucial factor. The results of the present review indicate that pazopanib carries a substantial risk of adverse events that can affect patient quality of life. However, the incidence of G3-G4 toxicities reported in the largest and most recent trial was 15% lower than that of previous studies. These data suggest an increasing familiarity with pazopanib over time due to its ł widespread use, and a better management of it side-effects. Overall, given that pazopanib seems to have a disease control rather than curative effect in NENs, quality of life should be take in consideration in future prospective studies.

Limitations
-----------

This study has some limitations. We conducted a comprehensive literature search with a sensitive search algorithm and an extensive manual search of reference lists and conference proceedings. However, we were unable to obtain additional unpublished data and are aware that a substantial amount of information is not available to the public. Another limitation is the low number of phase II clinical trials with different types of study design and populations included. Despite this, we believe that our results could provide important indications for the design of future dedicated clinical trials on NETs to underline the importance of head-to-head comparisons and the correct patient setting. Furthermore, the addition of SSAs to experimental drugs could be taken into consideration when designing dedicated trials on NETs.

Conclusions {#s5}
===========

Overall, our current pooled analyses of data on pazopanib in phase II studies are essentially consistent with the data available for other approved drugs. Surprisingly, although pazopanib was one of the first and most widely studied TKIs in neuroendocrine tumours, it has not moved to phase III. For this reason and because of the rarity of the disease, we decided to further investigate pazopanib activity in terms of DCR and mPFS. The clinical information available supports the use of pazopanib for the treatment of metastatic neuroendocrine tumours of different origin, especially those of the gastrointestinal tract.
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